Thermo Fisher (TMO) announced the UK Biobank Pharma Proteomics Project, or UKB-PPP, has selected its Olink Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher price target lowered to $585 from $620 at Evercore ISI
- 5 “Strong Buy” Healthcare Stocks to Buy Before They Soar in 2025
- Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls
- Scotiabank starts coverage on large cap life science tools trio
- Thermo Fisher initiated with a Sector Perform at Scotiabank